New Treatments for Homozygous Familial Hypercholesterolemia
Author Information
Author(s): Blom Dirk J., Marais A. David, Raal Frederick J.
Primary Institution: University of Cape Town
Hypothesis
What are the novel pharmacological therapies to lower LDL cholesterol in patients with homozygous familial hypercholesterolemia?
Conclusion
Most patients with homozygous familial hypercholesterolemia require multiple therapies to effectively lower LDL cholesterol levels.
Supporting Evidence
- Novel therapies can reduce LDL cholesterol by approximately 50%, regardless of LDL receptor function.
- Patients with homozygous familial hypercholesterolemia often require multiple therapies to achieve LDL cholesterol targets.
- Better control of LDL cholesterol is likely to improve patient outcomes.
Takeaway
Homozygous familial hypercholesterolemia is a condition that makes cholesterol levels very high, and new medicines can help lower these levels, but many patients need several different treatments to do so.
Methodology
This is a review of recent findings on pharmacological therapies for lowering LDL cholesterol in patients with homozygous familial hypercholesterolemia.
Limitations
The review does not provide new clinical trial data but summarizes existing studies and therapies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website